Solid lipid nanoparticles as drug delivery systems

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 27, Issue 2, 2005, Pages 127-144

  Manjunath, K ^a   Ready, J S ^a   Venkateswarlu, V ^a  

^a KAKATIYA UNIVERSITY   (India)

Author keywords

Controlled drug release; Formulation factors; Solid lipid nanoparticles; Targeted drug delivery

Indexed keywords

DRUG CARRIER; EMULSIFYING AGENT; EXCIPIENT; LIPID EMULSION; LIPOSOME; NANOPARTICLE; POLYMERIC NANOPARTICLE; SOLID LIPID NANOPARTICLE; SURFACTANT; UNCLASSIFIED DRUG;

CHEMICAL ANALYSIS; CHEMICAL COMPOSITION; COLLOID; CONTROLLED DRUG RELEASE; CRYSTALLIZATION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG RESEARCH; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; ELECTROLYTE BALANCE; FREEZE DRYING; GELATION; IN VITRO STUDY; IN VIVO STUDY; INSTRUMENT STERILIZATION; LIPID SOLUBILITY; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; POLYMERIZATION; REVIEW; SURFACE CHARGE; TARGETED DRUG DELIVERY;

DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EMULSIFYING AGENTS; LIPIDS; NANOSTRUCTURES; NANOTECHNOLOGY; PARTICLE SIZE; SOLUBILITY;

EID: 17044390370     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2005.27.2.876286     Document Type: Review

References (106)

1. Muller, R.H., Karsten, M., Sven, G. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the an. Eur J Pharm Biopharm 2000, 50: 161-77.
2. Stevens, P.J., Sekido, M., Lee, R.J. Synthesis and evaluation of hematoporphyrin derivative in a folate receptor-targeted solid lipid nanoparticle formulation. Anticancer Res 2004, 24(1): 161-5.
3. Mehenert, W., Mader, K. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 2001, 47: 165-96.
4. Zara, G.P., Cavalli, R., Bargoni, A., Funadaro, A., Vighetto, D., Gasco, M.R. Intravenous administration to rabbits of non-stealth and stealth doxorubicin loaded solid lipid nanoparticles at increasing concentration of stealth agent. Pharmacokinetics and tissue distribution of doxorubicin in brain and other tissues. J Drug Target 2002, 10(4): 327-35.
5. Hu, F.Q., Hong, Y., Yuan, H. Preparation and characterization of solid lipid nanoparticles containing peptide. Int J Pharm 2004, 273(1-2): 29-35.
6. Olbrich, C., Bakowsky, U., Lehr, C-M., Muller, R.H., Kneuer, C. Cationic solid lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Rel 2001, 77: 345-55.
7. Wissing, S.A., Muller, R.H. Solid lipid nanoparticles as carrier for sunscreens: In vitro release and in vivo skin penetration. J Control Rel 2002, 81: 225-33.
8. Stuchlik, M., Zak, S. Lipid-based vehicle for oral drug delivery. Biomed Papers 2001, 145(2): 17-26.
9. Westesen, K., Bunjes, H. Do nanoparticles prepared from lipids solid at room temperature always posses a solid lipid matrix? Int J Pharm 1995, 115: 129-31.
10. Jenning, V., Gohla, S. Comparison of wax and glyceride solid lipid nanoparticles (SLN). Int J Pharm 2000, 196: 219-22.
11. Jenning, V., Gohla, S.H. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencapsul 2001, 18(2): 149-58.
12. Westesen, K., Bunjes, H., Koch, M.H.J. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Rel 1997, 48: 223-36.
13. Westesen, K., Siekmann, B., Koch, M.H.J. Investigation on the physical state of lipid nanoparticles by synchrotron X-ray diffraction. Int J Pharm 1993, 93: 189-99.
14. Jores, K., Mehenert, W., Mader, K. Physicochemical investigations on solid lipid nanoparticles and on oil-loaded solid lipid nanoparticles: A nuclear magnetic resonance study 2003, 20(8): 1274-83.
15. Jenning, V., Thunemann, A.F., Gohla, S.H. Characterization of a novel solid lipid nanoparticles carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 2000, 199: 167-77.
16. Siekmann, B., Westesen, K. Submicron sized parenteral carrier systems based on solid lipids. Pharm Pharmacol Lett 1992, 1: 123-6.
17. Muller, R.H., Wallis, K.H. Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908. Int J Pharm 1993, 89: 25-31.
18. Olbrich, C., Gessner, A., Kayser, O., Muller, R.H. Lipid drug conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J Drug Target 2002, 10(5): 387-96.
19. Siekmann, B., Westesen, K. Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles. Colloid Surface B 1994, 3: 159-75.
20. Trotta, M., Debernardi, F., Caputo, O. Preparation of solid lipid nanoparticles by solvent emulsification-diffusion technique. Int J Pharm 2003, 257: 153-60.
21. Cavalli, R., Caputo, O., Marengo, E., Pattarino, F., Gasco, M.R. The effect of components of microemulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a series of model molecules. Pharmazie 1998, 53: 392-6.
22. Uner, M., Wissing, S.A., Yener, G., Muller, R.H. Influence of surfactants on the physical stability of solid lipid nanoparticle (SLN) formulations. Pharmazie 2004, 59: 331-2.
23. Westesen, K., Siekmann, B. Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles. Int J Pharm 1997, 151: 35-45.
24. Bummer, P.M. Physical chemical considerations of lipid based oral drug delivery-solid lipid nanoparticles. Crit Rev Ther Drug Carr Sys 2004, 21(1): 1-19.
25. Yu, B.T., Sun, X., Zhang, Z.R. Enhanced liver targeting by synthesis of N1-stearyl-5 Fu and incorporation into solid lipid nanoparticles. Arch Pharm Res 2003, 26(12): 1096-101.
26. Heiati, H., Tawashi, R., Philips, N.C. Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving, storage and lyophilization. J Microencapsul 1998, 15(2): 173-84.
27. Cavalli, R., Bargoni, A., Podio, V., Muntoni, E., Zara, O.P., Gasco, M.R. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 2003, 92(5): 1085-94.
28. Muller, R.H., Mehenert, W., Lucks, J.S. et al. Solid lipid nanoparticles (SLN)-An alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 1995, 41: 62-9.
29. Mulhen, A.Z., Schwarz, C., Mehenert, W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 1998, 45: 149-55.
30. Gasco, M.R. 1993. Method for producing solid lipid microspheres having narrow size distribution. US Patents 5 250 236.
31. Sjostrom, B., Bergenstahl, B. Preparation of submicron drug particles in lecithin stabilized o/w emulsions. I. Model studies of the precipitation of cholesteryl acetate. Int J Pharm 1992, 88: 53-62.
32. Siekmann, B., Westesen, K. Investigation on solid lipid nanoparticles prepared by precipitation in o/w emulsion. Eur J Pharm Biopharm 1996, 43: 104-9.
33. Venkateswarlu, V., Manjunath, K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Rel 2004, 95: 627-38.
34. Hu, F.Q., Yang, H., Zhang, H.H., Fang, M. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm 2002, 239(1-2): 121-8.
35. Schubert, M.A., Muller-Goymann, C.C. Solvent injection as a new approach for manufacturing lipid nanoparticles-Evaluation of the method and process parameters. Eur J Pharma Biopharm 2003, 55(1): 125-31.
36. Cavalli, R., Caputo, O., Carlotti, M.E., Trotta, M., Scarnecchia, C., Gasco, M.R. Sterilization and freeze-drying of drug-free and drug-loaded, solid lipid nanoparticles. Int J Pharm 1997, 148: 47-54.
37. Schwarz, C., Mehenert, W. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int J Pharm 1997, 157(2): 171-9.
38. Zimmemann, E., Muller, R.H., Mader, K. Influence of different parameters on reconstitution of lyophilized SLN. Int J Pharm 2000, 196(2): 211-3.
39. Freitas, C., Muller, R.H. Spray-drying of solid lipid nanoparticle (SLN™). Eur J Pharm Biopharm 1998, 46: 145-51.
40. Muller, R.H., Schwarz, C., Mehenert, W., Lucks, J.S. Production of solid lipid nanoparticles for controlled drug delivery. Proceedings of the International Symposium on Controlled Release Bioactive Materials, Vol. 20. 1993, 480-1.
41. Muller, R.H. In: Colloidal Carriers for Controlled Drug Delivery and Targeting. Wissenschaftliche Verlagsgesell schaft: Stuttgartuller, CRC Press: Bola Raton, 1991.
42. Schwarz, C., Mehenert, W. Solid lipid nanoparticles (SLN) for controlled drug delivery. U. Drug incorporation and physicochemical characterization. J Microencapsul 1999, 16(2): 205-13.
43. Illing, A., Unruch, T., Koch, M.H.J. Investigation on particle self-assembly in solid lipid based colloidal drug carrier systems. Pharm Res 2004, 21(4): 592-7.
44. Ahlin, P., Kristl, J., Sentjurc, M., Strancar, J., Pecar, S. Influence of spin probe structure on its distribution in SLN dispersions. Int J Pharm 2000, 196: 241-4.
45. Wissing, S.A., Muller, R.H., Manthei, L., Mayer, C. Structure characterization of Q10 loaded solid lipid nanoparticles by NMR spectroscopy. Pharmaceutical Research 2004, 21(3): 400-5.
46. Lukowski, G., Kasbohm, J., Pflegel, P., Illing, A., Wulf, H. Crystallographic investigation of cetylpalmitate solid lipid nanoparticles. Int J Pharm 2000, 196: 201-5.
47. Thoma, K., Serno, P. Thermoanalytischer nachweis der polymorphie der suppositoriengrundlage Hartfeit. Pharm Ind 1983, 45: 990-4.
48. Freitas, C., Muller, R.H. Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase. Eur J Pharm Biopharm 1999, 47(2): 125-32.
49. Schwarz, C., Mehenert, W., Lucks, J.S., Muller, R.H. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, Characterization and Sterilization. J Control Rel 1994, 30: 83-96.
50. Westesen, K., Siekmann, B. Biodegradable colloidal drug carrier systems based on solid lipids. In: Microencapsulation Methods and Industrial Applications. SimonBenita (Ed.). Marcel Dekkar, Inc.: New York, 1996.
51. Muller, R.H., Schwarz, C., Mehenert, W. Incorporation of lipophilic drugs and release profiles of solid lipid nanoparticles (SLN). Proceedings of the International Symposium on Controlled Release Bioactive Materials, Vol. 21. 1994, 146-7.
52. Bendas, B., Schmalfub, U., Neubert, R. Influence of propylene glycol as co-solvent on mechanisms of drug transport from hydrogel. Int J Pharm 1995, 116: 19-30.
53. Freitas, C., Muller, R.H. Stability determination of solid lipid nanoparticles (SLN™) in aqueous dispersion after addition of electrolyte. J Microencapsul 1999, 16(1): 59-71.
54. Zimmemann, E., Muller, R.H. Electrolyte- and pH-stabilities of aqueous solid lipid nanoparticles (SLN™) dispersions in artificial gastrointestinal media. Eur J Pharm Biopharm 2001, 52: 203-10.
55. Muller, R.H., Dorte, R., Stephan, A.R. Biodegradation of solid lipid nanoparticles as a function of lipase incubation time. Int J Pharm 1996, 144: 115-21.
56. Olbrich, C., Muller, R.H. Enzymatic degradation of SLN-Effect of surfactant and surfactant mixtures. Int J Pharm 1999, 180(1): 31-9.
57. Mosmann, T.R. Rapid colorimetic assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods 1983, 65: 55-63.
58. Scholer, N., Zimmermann, E., Katzfey, U., Hahn, H., Muller, R.H., Liesenfeld, O. Effect of solid lipid nanoparticles (SLN) on cytokine production and the viability of murine peritoneal macrophages. J Microencapsul 2000, 17: 639-50.
59. Maaben, S., Schwarz, C., Mehenert, W. Comparison of cytotoxicity between polyester nanoparticles and solid lipid nanoparticles (SLN). Proceedings of the International Symposium on Controlled Release Bioactactive Materials, Vol. 20. 1993, 490.
60. Muller, R.H., Ruhl, D., Runges, S., Schulze-Forster, K., Mehenert, W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res 1997, 14: 458-62.
61. Muller, R.H., Maaßen, S., Schwarz, C., Mehenert, W. Solid lipid nanoparticles (SLN) as potential carrier for human use; interaction with human granulocytes. J Control Rel 1997, 47: 261-9.
62. Scholer, N., Hahn, H., Muller, R.H., Liesenfeld, O. Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages. Int J Pharm 2002, 231: 167-76.
63. Scholer, N., Zimmermann, E., Katzfey, U., Hahn, H., Muller, R.H., Liesenfeld, O. Preserved solid lipid nanoparticles (SLN) at low concentrations do cause neither direct nor indirect cytotoxicity effects in peritoneal macrophages. Int J Pharm 2000, 196: 235-9.
64. Muller, R.H., Maaßen, S., Weyhers, H., Specht, F., Lucks J.S. Cytotoxicity of magnetite-loaded polylactide, polylactidelglycolide particles and solid lipid nanoparticles. Int J Pharm 1996, 138: 85-94.
65. Miglietta, A., Cavalli, R., Bocca, C., Gabriel, L., Gasco, M.R. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm 2000, 210: 61-7.
66. Pellizzaro, C., Coradini, D., Morel, S., Ligazio, E., Gasco, M.R. Daidone, M.G. Cholesteryl butyrate in solid lipid nanoparticles as an alternative approach. Anticancer Res 1999, 19(5B): 392-5.
67. Serpe, L., Laurora, S., Pizzimenti, S. et al. Cholesteryl butyrate solid lipid nanoparticles as a butyric acid pro-drug: Effects on cell proliferation, cell-cycle distribution and c-mye expression in human leukemic cells. Anticancer Drugs 2004, 15(5): 525-36.
68. Yang, S.C., Lu, L.F., Cai, Y., Zhu, J.B. Liang, B.W., Yang, C.Z. Body distribution in mice intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Rel 1999, 59(3): 299-307.
69. Cavalli, R., Zara, GP., Ugazio, E., Muntoni, E., Serpe, L., Gasco, M.R. Paclitaxel incorporated in solid lipid nanoparticles (SLN): Preliminary pharmacokinetic study and brain concentration. Proceedings of the 4th World Meet ADRITELF/APGI/APV (April 8-11, Florence) 2002, 669-70.
70. Fundaro, A., Cavalli, R., Bargoni, A., Vighetto, D., Zara, G.P., Gasco, M.R. Non stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: Pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res 2000, 42(4): 337-43.
71. Yang, S., Zhu, J., Lu, Y., Liang, B., Yang, C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999, 16(5): 751-7.
72. Jenning, V., Schafer-Korting, M., Gohla, S. Vitamin A-loaded solid lipid nanoparticles for topical use: Drug release properties. J Control Rel 2000, 66: 115-26.
73. Jenning, V., Gysler, A., Schafer-Korting, M., Gohla, S. Vitamine A loaded solid lipid nanoparticles for topical use: Occlusive properties and targeting to the upper skin. Eur J Pharm Biopharm 2000, 49(3): 211-8.
74. Maia, C.S., Mehenert, W., Schafer, K.M. Solid lipid nanoparticles as drug carrier for topical glucocorticoids. Int J Pharm 2000, 196(2): 165-7.
75. Dingler, A., Blum, R.P., Niehus, R.H., Gohla, S. Solid lipid nanoparticles (SLN/lipopearls)-A pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J Microencapsul 1999, 16(6): 751-67.
76. Lippacher, A., Muller, R.H., Mader, K. Investigation on viscoelastic properties of lipid based colloidal drug earners. Int J Pharm 2000, 196(2): 227-30.
77. Souto, E.B., Wissing, S.A., Barbosa, C.M., Muller, R.H. Development of a controlled release formulation based on SLN and NLC of topical clotrimazole delivery. Int J Pharm 2004, 278: 71-7.
78. Sznitowska, M., Gajewska, M., Janicki, S., Radwanska, A., Lukowski, G. Bioavailability of diazepam from aqueous-organic solution, submicron emulsion and solid lipid nanoparticles after rectal administration in rabbits. Eur J Pharm Biopharm 2001, 52: 159-63.
79. Cavalli, R., Morel, S., Gasco, M.R., Saettone, M.F., Chetoni, P. Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion-pair. Int J Pharm 1995, 117: 243-6.
80. Cavalli, R., Gasco, M.R., Chetoni, P., Burgalassi, S., Saettone, M.F. Solid lipid nanoparticles (SLN) as ocular delivery systems for tobramycin. Int J Pharm 2002, 238: 241-5.
81. Freitas, C., Muller, R.H. Effect of light and temperature on zeta-potential and physical stability in solid lipid nanoparticle (SLN™) dispersions. Int J Pharm 1998, 168: 221-9.
82. Demirel, M., Yazan, Y., Muller, R.H., Kilic, F., Bozan, B. Formulation and in vitro-in vivo evaluation of piribidil solid lipid micro and nanoparticles. J. Microencapsul 2001, 18(3): 359-71.
83. Zhang, Q., Yie, G., Li, Y., Yang, Q., Nagai, T. Studies on the cyclosporin A loaded stearic acid nanoparticles. Int J Pharm 2000, 200: 153-9.
84. Zara, G.P., Bargoni, A., Cavalli, R., Fundaro, A., Vighetto, D., Gasco, M.R. Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci 2002, 91(5): 1324-33.
85. Yang, S.C, Zhu, J.B. Preparation and characterization of camptothecin solid lipid nanoparticles. Drug Dev Ind Pharm 2002, 28(3): 265-74.
86. Cavalli, R., Peira, E., Caputo, O., Gasco, M.R. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with beta-cyclodextrins. Int J Pharm 1999, 182: 59-69.
87. Muller, R.H., Rudt, S. Optimization of a chemiluminescence based cell culture assay to study the affinity of surface-modified drug carriers to macrophages. Proceedings of the 18th International Symposium on Controlled Release Bioactive Materials, 1991, 219-20.
88. Bazile, D., Prud'homme, C., Bassoullet, M.T., Marlard, M., Spenlehauer, G., Veillard, M. Stealth Me.PEG-PLA Nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci 1995, 84: 493-8.
89. Moghimi, S.H., Hawley, A.E., Christy, N.M., Gray, T., Ilium, L., Davis, S.S. Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the lymph nodes. FEBS Lett 1994, 344: 25-30.
90. Gref, R., Domb, A., Quellec, P. et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 1995, 16: 215-33.
91. Moghimi, S.M. Mechanism regulating body distribution of nanospheres conditioning with pluronic and tetronic block copolymers. Adv Drug Deliv Rev 1995, 16: 183-93.
92. Koosha, F., Muller, R.H., Davis, S.S., Davis, M.C. The surface chemical structure of poly (beta-hydroxybutyrate) microparticles produced by solvent evaporation process. J Control Rel 1989, 9: 149-57.
93. Muller, R.H., Blunk, T. Properties of poloxamer and poloxamine coating layers on different sized polystyrene model drug carriers. Arch Pharm 1989, 322: 699.
94. Bocca, C., Caputo, O., Cavalli, R., Gabriel, L., Miglietta, A., Gasco, M.R. Phagocytic uptake of fluorescent stealth and nonstealth solid lipid nanoparticles. Int J Pharm 1998, 175: 185-93.
95. Muller, R.H., Maassen, S., Weyhers, M.W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) stabilized with poloxamine 908 and poloxamer 407. J Drug Target 1996, 4(3): 161-70.
96. Podio, V., Zara, G.P., Carazzone, M., Cavalli, R., Gasco, M.R. Bio distribution of stealth and nonstealth solid lipid nanospheres after intravenous administration to rats. J Pharm Pharmacol 2000, 52: 1057-63.
97. Wang, J.X., Sun, X., Zhang, Z.R. Enhanced brain targeting by synthesis of 3′, 5′-dioctonoyl-5 fluoro-2′-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm 2002, 54(30): 285-90.
98. Hodoshima, N., Udagawa, C., Ando, T., Fukuyasu, H., Watanabe, S., Nakabayashi, S. Lipid nanoparticles for delivering antitumor drugs. Int J Pharm 1997, 146: 81-92.
99. Stella, B., Arpicco, S., Peracchia, M.T. et al. Design of folic acid-conjugated nanoparticles for drug targeting. J Pharm Sci 2000, 89(11): 1452-64.
100. Lockman, P.R., Oyewumi, M.O., Kozizra, J.M., Rofer, K.E., Mumper, R.J., Allen, D.D. Brain uptake of thiamine-coated nanoparticles. J Control Rel 2003, 93: 271-82.
101. Igartua, M., Saulnier, P., Heurtault, B. et al. Development and characterization of solid lipid nanoparticles loaded with magnetite. Int J Pharm 2002, 233: 149-57.
102. Wissing, S.A., Muller, R.H. Soild lipid nanoparticles (SLN)-A novel carrier for UV blockers. Pharmazie 2001, 56(10): 783-6.
103. Kreuter, J., Liehl, E. Long term studies of microencapsulated and adsorbed influenza vaccine nanoparticles. J Pharm Sci 1980, 70: 367-71.
104. Almeida, A.J., Stephan, R., Muller, R.H. Peptide-loaded solid lipid nanoparticles (SLN): Influence of production parameters. Int J Pharm 1997, 149: 255-65.
105. Marengo, E., Cavalli, R., Caputo, O., Rodriguez, L., Gasco, M.R. Scale-up of the preparation process of lipid solid nanospheres: Part 1. Int J Pharm 2000, 205: 3-13.
106. Gohla, S.H., Dingler, A. Scaling up feasibility of the production of solid lipid nanoparticles (SLN™). Pharmazie 2001, 56(1): 61-3.